VUB13_FXS
The cell line is not validated yet.
VUBe013-A
General
Cell Line |
|
| hPSCreg name | VUBe013-A |
| Cite as: | VUBe013-A (RRID:CVCL_9849) |
| Alternative name(s) |
VUB13_FXS
|
| Cell line type | Human embryonic stem cell (hESC) |
| Similar lines |
|
| Last update | 27th April 2022 |
| User feedback | |
Provider |
|
| Generator | Vrije Universiteit Brussel (VUB) |
| Derivation country | Belgium |
External Databases |
|
| Cellosaurus | CVCL_9849 |
| Wikidata | Q54993398 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Ethics
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Alternative consent approval number | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| How may genetic information associated with the cell line be accessed? | |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Federal Commission Medical and Scientific Research on embryos in vitro (Belgium) |
| Approval number |
hESC Derivation
| Date of derivation | 2006-09-19 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
No
Other hESC source:
IVF
|
| PGD Embryo? |
Yes |
| Cell isolation | Mechanical |
| Cell seeding | Isolated ICM |
Culture Conditions
| Surface coating | MEF | |||||||||
| O2 Concentration | 20 % | |||||||||
| CO2 Concentration | 10 % | |||||||||
| Medium |
Other medium:
Base medium: Knockout-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| DNMT3B |
Yes |
|
||||
| GDF3 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| ZFP42 (REX-1) |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| SSEA-1 |
No |
|
||||
| Lin28 |
Yes |
|
||||
| NPM1 |
Yes |
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Passage number: 30
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.